» Articles » PMID: 36675152

Classes of Lipid Mediators and Their Effects on Vascular Inflammation in Atherosclerosis

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Jan 21
PMID 36675152
Authors
Affiliations
Soon will be listed here.
Abstract

It is commonly believed that the inactivation of inflammation is mainly due to the decay or cessation of inducers. In reality, in connection with the development of atherosclerosis, spontaneous decay of inducers is not observed. It is now known that lipid mediators originating from polyunsaturated fatty acids (PUFAs), which are important constituents of all cell membranes, can act in the inflamed tissue and bring it to resolution. In fact, PUFAs, such as arachidonic acid (AA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), are precursors to both pro-inflammatory and anti-inflammatory compounds. In this review, we describe the lipid mediators of vascular inflammation and resolution, and their biochemical activity. In addition, we highlight data from the literature that often show a worsening of atherosclerotic disease in subjects deficient in lipid mediators of inflammation resolution, and we also report on the anti-proteasic and anti-thrombotic properties of these same lipid mediators. It should be noted that despite promising data observed in both animal and in vitro studies, contradictory clinical results have been observed for omega-3 PUFAs. Many further studies will be required in order to clarify the observed conflicts, although lifestyle habits such as smoking or other biochemical factors may often influence the normal synthesis of lipid mediators of inflammation resolution.

Citing Articles

rs671 Polymorphism is Associated with Susceptibility of Coronary Atherosclerosis in Patients with Hypertension.

Hou H, Huang S, Huang W, Huang L, Zhang Z, Liang L Int J Gen Med. 2025; 18:681-690.

PMID: 39959460 PMC: 11827492. DOI: 10.2147/IJGM.S501396.


The Cardioprotective Effects of Polyunsaturated Fatty Acids Depends on the Balance Between Their Anti- and Pro-Oxidative Properties.

Sidorkiewicz M Nutrients. 2024; 16(22).

PMID: 39599723 PMC: 11597422. DOI: 10.3390/nu16223937.


Polyunsaturated Fatty Acids as Potential Treatments for COVID-19-Induced Anosmia.

Wang Y, Lin C, Huang C Biomedicines. 2024; 12(9).

PMID: 39335598 PMC: 11428228. DOI: 10.3390/biomedicines12092085.


Targeting immune cell recruitment in atherosclerosis.

Doring Y, van der Vorst E, Weber C Nat Rev Cardiol. 2024; 21(11):824-840.

PMID: 38664575 DOI: 10.1038/s41569-024-01023-z.


Lipid-Sensing Receptor FFAR4 Modulates Pulmonary Epithelial Homeostasis following Immunogenic Exposures Independently of the FFAR4 Ligand Docosahexaenoic Acid (DHA).

Sveiven S, Anesko K, Morgan J, Nair M, Nordgren T Int J Mol Sci. 2023; 24(8).

PMID: 37108233 PMC: 10138935. DOI: 10.3390/ijms24087072.

References
1.
Fredman G, Van Dyke T, Serhan C . Resolvin E1 regulates adenosine diphosphate activation of human platelets. Arterioscler Thromb Vasc Biol. 2010; 30(10):2005-13. PMC: 2982748. DOI: 10.1161/ATVBAHA.110.209908. View

2.
Zhang C, Baker D, Yasuda S, Makarova N, Balazs L, Johnson L . Lysophosphatidic acid induces neointima formation through PPARgamma activation. J Exp Med. 2004; 199(6):763-74. PMC: 2212723. DOI: 10.1084/jem.20031619. View

3.
Filep J, Zouki C, Petasis N, Hachicha M, Serhan C . Anti-inflammatory actions of lipoxin A(4) stable analogs are demonstrable in human whole blood: modulation of leukocyte adhesion molecules and inhibition of neutrophil-endothelial interactions. Blood. 1999; 94(12):4132-42. View

4.
Hao H, Hu S, Wan Q, Xu C, Chen H, Zhu L . Protective Role of mPGES-1 (Microsomal Prostaglandin E Synthase-1)-Derived PGE (Prostaglandin E) and the Endothelial EP4 (Prostaglandin E Receptor) in Vascular Responses to Injury. Arterioscler Thromb Vasc Biol. 2018; 38(5):1115-1124. PMC: 5920701. DOI: 10.1161/ATVBAHA.118.310713. View

5.
Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S . Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med. 2005; 201(5):713-22. PMC: 2212834. DOI: 10.1084/jem.20042031. View